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Filoviruses are the cause of severe hemorrhagic fever in human and nonhuman primates. The envelope glycoprotein (GP), re-
sponsible for both receptor binding and fusion of the virus envelope with the host cell membrane, has been demonstrated to in-
teract with multiple molecules in order to enhance entry into host cells. Here we have demonstrated that filoviruses utilize gly-
cosaminoglycans, andmore specifically heparan sulfate proteoglycans, for their attachment to host cells. This interaction is
mediated by GP and does not require the presence of the mucin domain. Both the degree of sulfation and the structure of the
carbohydrate backbone play a role in the interaction with filovirus GPs. This new step of filovirus interaction with host cells can
potentially be a new target for antiviral strategies. As such, we were able to inhibit filovirus GP-mediated infection using carra-
geenan, a broad-spectrummicrobicide that mimics heparin, and also using the antiviral dendrimeric peptide SB105-A10, which
interacts with heparan sulfate, antagonizing the binding of the virus to cells.
Filoviruses are among the most virulent pathogens that affecthumans, causing viral hemorrhagic fever (1). The family is
comprised of the Marburgvirus (MARV) genus, with various
strains of Lake Victoria MARV, and the Ebolavirus genus, with 5
species, Sudan ebolavirus (SUDV), Zaire ebolavirus (EBOV), Taï
Forest ebolavirus (TAFV), Reston ebolavirus (RESTV), and
Bundibugyo ebolavirus (BEBOV). More recently, a new genus has
been proposed after the identification of the provisionally named
Lloviu virus (LLOV) in dead insectivorous bats found in caves in
France, Spain, and Portugal in 2002 (2). LLOV is genetically dis-
tinct, and pathogenicity in humans is not yet established. SUDV
and EBOV, as well as MARV, have caused several large epidemics
of severe hemorrhagic fever in humans, while TAFV has so far
infected one person, who recovered. The most recently identified
species, BEBOV, caused an outbreak in 2007 with 131 cases and a
37% case fatality rate. RESTV, however, appears to be nonpatho-
genic in humans, although it can cause lethal illness in nonhuman
primates. Virus entry and attachment are mediated by a single
envelope glycoprotein (GP) that contains the receptor-binding
domain (RBD) and acts as a class I fusion protein (3, 4). The
mucin-like (muc) domain within GP containsmultiple sites of N-
and O-linked glycosylation and has been linked to virus attach-
ment to the human macrophage galactose- and N-acetylgalac-
tosamine-specific C-type lectin (hMGL) (5) enhancing infection
of target cells. This domain is responsible for loss of cell adherence
in culture (6), and its removal has been shown to increase pseu-
dotyped virus infectivity (3). Filoviruses infect and kill a wide
range of host cells, and several cell surface proteins have been
reported to be virus receptors or attachment factors, including
C-type lectins (5, 7–9), 1 integrin adhesion receptors (10), and
folate receptor alpha (FR-) (11). T-cell immunoglobulin and
mucin domain 1 (TIM-1) (12) has been shown to interact directly
with the RBD at the cell surface, although this molecule is not
present on all permissive cells. Taken together, these findings sug-
gest that filoviruses utilize a combination of attachment and re-
ceptor molecules to enter cells, resulting in their broad host cell
range. Following attachment, virus is internalized via macropi-
nocytosis (13, 14) and translocated to cellular compartments,
where GP is cleaved by endosomal proteases, predominantly ca-
thepsin B (15). Subsequent to proteolysis, exposure of the RBD
allows GP to specifically interact with Niemann-Pick C1 (NPC1),
a cholesterol transporter present in late endosomal membranes
(16–18).
Proteoglycans are widely distributedmolecules, consisting of a
transmembrane protein linked to sulfated glycosaminoglycans
(GAGs). GAGs, typified by heparan sulfate (HS), are long (20 to
70 monosaccharides), unbranched, and negatively charged poly-
saccharides that are present on the surfaces of nearly all cells but
are heterogeneous with respect to their compositions and quanti-
ties between different species, cell types, tissues, and developmen-
tal stages. The carbohydrate in cell surface proteoglycans is ex-
ploited by a number of viruses for cell surface attachment (19).
Viruses usingGAGs include the herpes simplex viruses (HSV) (20,
21), human papillomavirus (HPV) (22), cytomegalovirus (CMV)
(23), vaccinia virus (24), Sindbis virus (25), respiratory syncytial
virus (RSV) (26, 27), noroviruses (28), adeno-associated virus
(29), dengue virus (30), hepatitis C virus (31), human immuno-
deficiency virus type 1 (HIV-1) (32), and human T-cell leukemia
virus (33). In themajority of cases, virus-cell interactions use pro-
teoglycans, mainly heparan sulfate proteoglycans (HSPG), as ini-
tial attachment factors for the viral envelope, although sometimes
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proteoglycans can act as fusion receptors. Often these virus-car-
bohydrate interactions are involved in directing specific tissue tro-
pism.
In the present study, the possible role of GAGs in filovirus
GP-mediated infectionwas examined. For this, we analyzed direct
binding, inhibition by soluble GAGs and GAG analogs, and enzy-
matic removal of the GAGs from the cell surface, as well as inhi-
bition by GAG-binding peptides.
MATERIALS AND METHODS
Cells and cell culture. The adherent cell lines 293T, Vero, Huh7, and
Huh7.5 were cultured in Dulbecco’s modified Eagle medium (DMEM)
supplemented with 10% fetal bovine serum (FBS) and penicillin-strepto-
mycin (15 U/ml). Human endothelial cells (Clonetics, Hopkinton, MA)
were cultured in Clonetics endothelial cell basal medium. Human pri-
mary monocyte-derived macrophages were isolated as previously de-
scribed (34) and cultured in RPMI supplementedwith 10%human serum
and penicillin-streptomycin (15 U/ml).
Fetal livers were obtained from elective abortions with the approval of
the Committee for Human Research at the University of California, San
Francisco, and with the consent of the women undergoing the procedure.
Midgestation specimens were used, with the gestational age of the tissues
estimated based on the foot length of the fetus. Fetal liver parenchymal
cells were isolated by enzymatic digestion and depletion of erythrocytes as
previously described (35).
Plasmids.Mammalian expression plasmids for EBOV, EBOV muc,
RESTV, TAFV, and SUDVGPs have been described previously (6). cDNA
encoding theMARVRavnGPwas amplified by PCR utilizing the forward
primer 5= TAGAATTCACCATGAAGACCATATATTTTCTGATTAGTC
TC3=, including EcoRI (in bold), the Kozac sequence (in italics), andATG
(in italics) and the reverse primer 5=TAGCTAGCTCATCCAATGTATTT
AGTGAAGATACG3=, including NheI (in bold) and a stop codon, and
subcloned into the mammalian expression plasmid pCAGGS (36) using
EcoRI and NheI.
Pseudotype andVLPproduction. Lentiviral pseudotypes harboring a
heterologous GP were produced essentially as described previously (37)
by using 10 g of the HIV-based luciferase vector (pNL-luc, based on
pNL3-4-R-E-) (38) and 30 g of plasmid-encoding viral envelope. Viri-
ons were subjected to ultracentrifuge concentration at 28,000 rpm in an
SW28 rotor (Beckman) through a 20% sucrose cushion for 1.5 h at 4°C.
The pellets were resuspended overnight in Hanks balanced salt solution
(HBSS) at 4°C. Virus-like particles (VLPs) were produced by CaCl2 trans-
fection of 293T cells with a 2:1 ratio of Bla-VP40 and the plasmids encod-
ing the viral envelope, as described in reference 9.
Heparin-Sepharose binding. HiTrap heparin HP-coated Sepharose
beads from 1-ml columns (mean particle size of 34 m; GE Healthcare)
were taken out of the column and washed twice in phosphate-buffered
saline (PBS) and once in binding buffer (10 mM sodium phosphate, pH
7). Washed beads (50 l) were then added to 20 l of the different con-
centrated pNluc pseudotypes and incubated with mixing for 10 min. The
beads were washed three times in binding buffer, and then 100 l of
elution buffer (10 mM sodium phosphate [pH 7] and 2 M NaCl) was
added and incubated with mixing for 10 min. Supernatant was removed
to another tube. Eight microliters of the same concentrated pNluc pseu-
dotypes and 40l of the eluate supernatants were inactivatedwith 10l of
0.1% Triton in PBS. Sample buffer and reducing agent were added, and
the samples were analyzed by SDS-PAGE using a 10% Bis-Tris gel (Invit-
rogen). The separated proteins were transferred to a nitrocellulose mem-
brane and blocked with 2% powdered milk in Tris-buffered saline (TBS)
for 30 min. at room temperature. The membrane was then incubated in
TBS–0.05% Tween 20 with a 1:200 dilution of anti-p24 mouse sera to
detect lentivirus-associated HIV p24 for 1 h at room temperature. After 3
washes, 10 min each, with TBS–0.05% Tween 20, the membrane was
incubated with a 1:5,000 dilution of peroxidase-conjugated goat anti-
mouse antibody (Thermo Scientific, Fremont, CA) for 1 h at room tem-
perature. The membrane was then washed with TBS–0.05% Tween 20
three times for 10min each, and immunoreactive proteins were visualized
using an ImageQuant LAS 400 imager (GEHealthcare) after development
with a Pierce ECL Plus substrate kit (Thermo Scientific).
Inhibition of infection by soluble glycosaminoglycans andby carra-
geenan. Cells were seeded at 2 104 in 96-well plates 24 h prior to infec-
tion. Medium was removed, and the cells were incubated with the appro-
priate amounts of viral supernatant in 100 l of medium containing
cell-culture-grade heparin, chondroitin sulfate A, dermatan sulfate (also
known as chondroitin sulfate B), heparan sulfate, or carrageenan type V
(Sigma) for 2 h at 37°C. Supernatant was removed, and 200 l of fresh
medium was added to the cells, followed by incubation for 48 h at 37°C.
Virus infection was analyzed by measuring the luciferase activity from
the cell lysates as per the manufacturer’s instructions (Promega, Sunny-
vale, CA).
Heparinase treatment. Cells were seeded at 2 104 in 96-well plates
24 h prior to infection. Medium was removed, and the cells were incu-
bated with heparinase I from Flavobacterium heparinum (Sigma,Wiscon-
sin) in 20 mM Tris-HCl (pH 7.5), 4 mM CaCl, 50 mM NaCl, and 0.01%
bovine serumalbumin (BSA) or heparinase III from Flavobacteriumhepa-
rinum (Sigma) in 20mMTris-HCl (pH 7.5), 4 mMCaCl, and 0.01% BSA
for 1 h at room temperature (RT) and thenwashed twice with PBS. To test
the effect on HIV pseudotype infectivities, we then added the appropriate
amounts of viral supernatant in 50l of medium and incubated for 2 h at
37°C. Supernatant was removed, and 200 l of fresh medium was added
to the cells and incubated for 48 h at 37°C. Virus infectionwas analyzed by
measuring the luciferase activity from the cell lysates as per the manufac-
turer’s instructions (Promega). To test the effect on Bla-VP40 VLP trans-
duction efficiency, the cells were spin inoculated at 2,225 rpm for 90 min.
at 21°C and then incubated for 3 h at 37°C. GP-mediated transfer of
functional -lactamase enzymatic activity to the cytoplasm of target cells
was measured by labeling cells with CCF2-AM as per the manufacturer’s
instructions (GeneBLAzer detection kit; Life Technologies) and analyzed
by fluorescence microscopy using a 405-nm excitation filter, a 425-nm
dichroic filter, and a 435-nm long-pass emission filter to visualize green
and blue cells simultaneously (Chroma Technologies).
Inhibition of infection by dendrimeric peptides.Cells were seeded at
2  104 in 96-well plates 24 h prior to infection. Medium was removed,
and the cells were incubated with the appropriate amounts of the dendri-
meric peptides SB105-A10 (Spider Biotech, Colleretto Giacosa, Italy) or
SB104 (CPC Scientific, Sunnyvale, CA) in 50l of medium for 2 h at 4°C.
Then, the appropriate amounts of viral supernatant in 50 l of medium
were added and incubated for 2 h at 37°C. Supernatant was removed, and
200 l of fresh medium was added to the cells and incubated for 48 h at
37°C. Virus infection was analyzed by measuring the luciferase activity
from the cell lysates as per the manufacturer’s instructions (Promega).
EBOV infectivity assay. Zaire EBOV (kikwit) was kindly provided by
Peter Jahrling. The filovirus stock was grown in Vero E6 cells in 150-mm
tissue culture flasks with DMEM (Invitrogen) containing 4,500 mg/liter
D-glucose, L-glutamine, and supplemented with 2% heat-inactivated FBS
(DMEM-2) at 37°C, 5%CO2, and 85% humidity. At 8 days postinfection,
supernatant was collected, and aliquots of the virus were stored at80°C.
EBOV is a risk group 4 (CDC) and category A (NIH) agent. All experi-
ments with this virus were performed within the biosafety level 4 (BSL4)
facility at the Texas Biomedical Research Institute (formerly Southwest
Foundation for Biomedical Research) in SanAntonio, TX. Personnel han-
dling live virus wore appropriate protective equipment (positive-pressure
biosafety suit). All virus manipulations were performed under BSL-4
maximum biocontainment within a biosafety laminar flow hood.
For the infectivity assay, Vero cells (3 105 cells/well) were seeded in
a 6-well plate 24 h prior to infection in DMEM (Invitrogen) containing
D-glucose (4,500 mg/liter) and L-glutamine and supplemented with 2%
heat-inactivated FBS (DMEM-2). The cells were incubated for 2 h with
compound before infection with EBOV for an additional 30 min at a
multiplicity of infection (MOI) of 1. The inoculum was then removed,
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and fresh medium with the compound at the same concentration was
added. At day 8 postinfection, supernatant was harvested and used in a
conventional plaque assay. For the plaque assay, cells were seeded as de-
scribed above in a 6-well plate 24 h prior to performing the assay. On the
day of assay, samples were serially diluted in PBS and incubated for 1 h in
duplicate wells of a 6-well plate. Following the 1-h adsorption period,
samples were removed, and the monolayer was overlaid with DMEM-2
containing methylcellulose. The plates were then incubated for 10 days at
37°C 2°C. On day 10, the overlay was removed, and cells were stained
with crystal violet. Plaques were enumerated by directly visualizing them
on the monolayer using a dissecting microscope. Only plates with plaque
numbers ranging from 25 to 250 were counted to avoid overlap or low
representation.
RESULTS
Filovirus glycoprotein-dependent binding to heparin. Viral
pseudotypes have become an ideal tool to investigate cell entry of
filoviruses without safety concerns (10, 39). In the present study,
we initially wished to study whether filovirus GP could bind to
glycosaminoglycans. Thus, binding of filovirus GP to immobi-
lized heparin was tested. Heparin-Sepharose beads were used to
capture and precipitate lentiviral particles pseudotyped with
EBOV, RESTV, SUDV, and TAFV GP, as well as the GP of EBOV
lacking a mucin-like domain (with deletion of amino acids at po-
sitions 311 to 462, termed “muc”) and Lake Victoria MARV.
Lentiviral pseudotypes bearing an unrelated GP from Lassa virus,
as well as envelope GP-deficient pseudotypes, were used as con-
trols. Heparin-bound particles were eluted and analyzed for the
presence of HIV p24 antigen (Fig. 1). Heparin beads captured all
of the particles bearing filovirus envelopes, including EBOV
muc, suggesting that the mucin domain is not absolutely re-
quired for interactions with heparin. The interaction is dependent
on the presence of GP, since GP-deficient pseudotypes were un-
able to bind heparin, as were particles bearing Lassa virus GP.
Addition of soluble heparinwas able to elute boundfilovirus pseu-
dotypes from the heparin beads at a concentration of 50 mg/ml
(data not shown), proving the specificity of this interaction. These
results demonstrate that filovirus GPs, but not Lassa virus GP,
possess the ability to bind heparin.
Soluble GAG inhibition of filovirus GP-mediated infection.
To determine whether the interaction with GAGs, such as hepa-
rin,might have an effect on filovirus GP-mediated infection, 293T
cells were infected with infectivity-normalized pseudotypes bear-
ing the different filoviral GPs and Old World arenavirus Lassa
virus in the presence or absence of different concentrations of
soluble heparin or the related ligands, chondroitin sulfate A
(CSA), dermatan sulfate (DS), and heparan sulfate (HS) (Fig. 2A).
Inhibition of infection was detected even with the lowest concen-
tration of soluble GAGs for all the filovirus GPs, including EBOV
muc, but not for Lassa virus when utilizing heparin, CSA, and
DS. Inhibition was similar for the different GPs, with the excep-
tion of TAFV, which, although significantly inhibited byHP, CSA,
and DS at the highest concentrations of each (P 0.05), was less
affected by the presence of all the GAGs. This difference was sta-
tistically significant (P 0.01 when comparing TAFV to EBOV).
Although variations in the incorporation efficiency of GP are ap-
parent, the differences inGAG inhibitionwere notmerely a reflec-
tion of levels of expression, since EBOV, SUDV, and TAFV bear-
ing V5 epitope tags on their C termini were expressed at broadly
similar levels (Fig. 2B) despite the differences in inhibition that
were observed (Fig. 2A). Inhibition of EBOV by heparin was fur-
ther confirmed utilizing murine leukemia virus (MLV)-based
pseudotypes, while MLV pseudotypes bearing Lassa virus GP and
five different New World arenavirus GPs (Pichide, Flexal, Tac-
aribe, Guaranito and Carvallo strains) were not affected (data not
shown). Inhibition of infection by DSwas significantly lower than
that by heparin and CSA (Fig. 2A), indicating that the inhibitory
effect of GAGs on transduction is mediated by both electrostatic
charge and the sequence of the carbohydrate moieties. No effect
was observedwith the less sulfatedHS for any of the viruses tested,
suggesting that the degree of sulfation is also an important factor
in the interaction of the GAG with the filovirus GPs. While filovi-
rus GP-mediated infection was almost completely abrogated,
Lassa virus GP pseudotypes were not affected by any of the GAGs
tested, even at the highest concentration. This confirms that infec-
tion mediated by Lassa virus GP is independent of GAGs. Similar
results were obtained in Vero cells (data not shown), indicating
that the effect is not cell type specific.
Inhibition of filovirus GP-mediated infection in primary
cells representingmajor targets of filovirus infection.To further
determine the relevance of GP/GAG interactions for infection, we
decided to analyze the effect of soluble heparin in the infection of
primary human endothelial and liver cells and macrophages,
which represent some of the primary targets for in vivo filovirus
infection. Heparin was able to inhibit infection mediated by
EBOVGP in human umbilical vein endothelial cells (HUVEC) by
up to 90% and TAFV GP by up to 30% (Fig. 3A). Similar results
were obtained with human pulmonary artery endothelial cells
(data not shown). Infection of human primary fetal liver cells by
the different Ebola virus pseudotypes was also strongly affected
(almost 100% for EBOV, RESTV, and SUDV and up to 60% for
TAFV) by the addition of soluble heparin (Fig. 3B). Finally, both
EBOV and MARV Ravn but not Lassa virus pseudotype infection
of humanmacrophages was also inhibited by heparin in a concen-
tration-dependent manner, with a more than 50% reduction in
infectivity (Fig. 3C). These results confirm that targeting GAG
binding by using soluble heparin inhibits the interaction of the
filoviral GPs with its natural target cells.
Enzymatic removal of glycosaminoglycans decreases cell
susceptibility tofilovirusGP-mediated infection.Heparinasedi-
gestion of cells was used to examine the effect of removal of HS
(40). Infectivity was evaluated after digestion of 293T cells with
heparinase I (which cleaves heparin andHS [41]) or heparinase III
(which cleaves onlyHS [41]). Digestion of 293T cells with increas-
ing concentrations of either heparinase I or III resulted in a max-
imum reduction of EBOV and MARV pseudotype infectivity of
approximately 50% regardless of the enzyme used, while infectiv-
FIG 1 Binding of filovirus GP to immobilized heparin. Concentrated lentivi-
ral pseudotypes bearing the different filovirus envelope glycoproteins, Lassa
virus envelope glycoprotein, or no envelope were incubated with heparin-
Sepharose beads. After several washes, bound virus was subsequently eluted
with 2MNaCl. Heparin-bound virus was detected by SDS-polyacrylamide gel
electrophoresis and Western blotting for the p24 protein.
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FIG 2 Soluble GAGs inhibit filovirus GP-mediated infection of 293T cells. (A) 293T cells were infected with concentratedHIV pseudotypes bearing the different
filovirus envelope glycoproteins and Lassa virus envelope glycoprotein in the presence or absence of different concentrations of soluble heparin, chondroitin
sulfate A, dermatan sulfate, or heparan sulfate. Results are expressed as relative light units (RLU) and represent the means SD for duplicate wells. The results
are representative of at least three different experiments. Statistics consisted of on one-way analysis of variance (ANOVA) followed byBonferroni posttests. ,P
0.05; , P 0.01; , P 0.001. (B) HIV pseudotypes were subjected to SDS–10% PAGE, transferred to nitrocellulose, and immunoblotted for the presence
of the C-terminal V5 epitope using mouse anti-V5. Anti-p24 was used as a loading control.
Salvador et al.
3298 jvi.asm.org Journal of Virology
ity of Lassa virus pseudotypes remained unaffected (Fig. 4A). This
effect was not cell type specific, since treatment of Huh7 cells with
heparinase I also resulted in a dose-dependent reduction of up to
50% of filovirus pseudotype infectivity (Fig. 4A). The entry path-
ways of lentivirus pseudotypes are generally thought to faithfully
mimic authentic virus entry. However, Ebola virus particles are
filamentous, pleomorphic, andmorphologically distinct from ret-
rovirus particles, which are usually spherical. Thus, we decided to
confirm the results with Bla-VP40 VLPs, which are morphologi-
cally similar to Ebola virus particles (9, 42). Consistent with the
pseudovirus results, heparinase I treatment of primary HUVEC
cells also resulted in a significant (P  0.001) 50% reduction of
EBOV VLP transduction (Fig. 4B). The fact that removal of hep-
arin and/or HS significantly affected the ability of filovirus GP to
mediate infectivity/fusion further indicates that cell surface GAGs
contribute greatly to attachment of filoviruses to target cells.
Explorationof potential antivirals exploitingGP/GAG inter-
actions. Carrageenan, a type of sulfated polysaccharide extracted
from red algae, has been reported to inhibit the infection of several
human viral pathogens that utilize HS as an attachment factor,
such as HPV, dengue virus (43), HSV, CMV, VSV, and HIV (44–
48). Thus, the activity of carrageenan ismost likely based on struc-
FIG 3 Soluble heparin inhibits EBOV GP-mediated infection of human primary umbilical vein endothelial cells (A), human fetal liver cells (B), and human
macrophages (C), which represent main targets of filovirus natural infection. The cells were infected with concentrated HIV pseudotypes bearing the different
filovirus envelope glycoproteins in the presence or absence of different concentrations of soluble heparin (g/ml). Results are expressed as relative light units
(RLU) and represent the means  SD for duplicate wells. The results are representative of at least two different experiments. Statistics consisted of one-way
ANOVA followed by Bonferroni posttests. , P 0.05; , P 0.01; , P 0.001.
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tural similaritieswith theHS residues of cellmembrane proteogly-
cans. Like heparin, 	-carrageenan is more heavily sulfated than
most tissue-derived heparan sulfate. Our data indicate that effi-
cient filovirus GP-mediated infection requires GAGs and more
specifically HS. Thus, to investigate the concept that 	-carra-
geenan chemically mimics HS and thereby can antagonize HS-
dependent virus attachment, we tested its effectiveness for inhib-
iting filovirus pseudotype infectivity. As expected, a strong dose-
dependent inhibition of pseudotypes bearing filovirus envelopes
was observed in Huh7 and 293T cells (Fig. 5 and data not shown)
in the presence of soluble 	-carrageenan, while infectivity of the
HS-independent Lassa virus pseudotypeswas not affected. Similar
results were obtained with MLV-based pseudotypes in Vero cells,
confirming that EBOV but not Lassa virus, or themajority of New
World arenavirus envelopes, was strongly inhibited (data not
shown).
A peptide dendrimer, SB105-A10, has been developed as a po-
tent inhibitor of several viruses, including HSV-1 and -2 (49),
HPV (50), CMV (51,) and HIV-1 (A. Giuliani, S. Landolfo, D.
Lembo, D. Gibellini, G. Pirri, L, Pizzuto, and G. Gribaudo, Italian
patent applicationMI2009A001425). SB105-A10 exerts its inhibi-
tion by binding to HS on the cell surface and thus antagonizes
virus attachment to the target cells (49–51). This novel peptide-
derivatized dendrimer is based on the M6 prototype (52), a tetra-
branched dendrimer synthesized on a lysine core, which tethers
four 10-mer peptide chains in lysine alpha and epsilon positions.
These functional units contain clusters of basic amino acids that
bind to the negatively charged sulfate and carboxyl groups of HS.
Peptide-derivatized dendrimers have been shown to be highly
resistant to blood proteases and to have low hemolytic activity and
little cytotoxic effect against eukaryotic cells, making them prom-
ising candidates for the development of new antibacterial/antivi-
ral drugs (52, 53).We tested SB105-A10 as a possible inhibitor for
filovirus pseudotypes. Pretreatment of Huh7 cells with SB105-
A10 1 h before infection produced a significant concentration-
dependent inhibition of both MARV and EBOV pseudotypes
(Fig. 6). This antiviral activity was not due to cytotoxicity, since
infection by Lassa virus pseudotypes remained unaffected even at
high peptide concentrations. The inhibitory effect is neither virus
strain specific nor cell type specific, since similar effects were ob-
served in 293T cell infection with three additional Ebola virus GPs
(data not shown). Although they differ only in the specific amino
acid sequence of the peptide surface groups attached to the den-
drimer scaffold (49), dendrimeric peptide SB104 showedminimal
inhibitory activity compared to that of SB105-A10 for CMV infec-
tion (51). When SB104 was used as a negative control in parallel
with SB105-A10, it showed little inhibitory activity and only at
FIG 4 HSPGs mediate attachment of filovirus to the cells. 293T, Huh7, and
HUVEC cells were pretreated ormock treated with different amounts of hepa-
rinase I or heparinase III and exposed to concentrated HIV pseudotypes bear-
ing EBOV, MARV, or Lassa virus envelope glycoproteins (A) or EBOV and
Lassa virus -lactamase-based VLPs (B). Results are expressed as percentages
of results with noheparinase and represent themeans SD for duplicatewells.
Heparinase concentrations are expressed in units. The results are representa-
tive of at least three different experiments.
FIG 5 Sulfated polysaccharide 	-carrageenan inhibits filovirus GP-mediated
infection. Huh7 cells were infected with concentrated HIV pseudotypes bear-
ing EBOV, MARV, or Lassa virus envelope glycoproteins in the presence or
absence of different concentrations of 	-carrageenan. Results are expressed as
percentages of no 	-carrageenan and represent the means SD for duplicate
wells. The results are representative of at least three different experiments.
Similar results were observed with 293T cells (data not shown).
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high concentrations against MARV pseudotypes, indicating that,
as with the other HS-dependent viruses, the inhibitory activity of
the SB105-A10 dendrimeric peptide toward filovirus stems from
the specific amino acid sequence of the peptides.
Inhibitionbyheparinandotherpolysaccharides is also effec-
tive against wild-type EBOV. In order to further study the inhib-
itory properties against filoviruses of heparin and analog mole-
cules, such as carrageenan, both compounds were evaluated as
inhibitors of replication-competent EBOV in a plaque reduction
assay with Vero cells (Fig. 7). Both heparin (50% inhibitory con-
centration [IC50]
 8) and carrageenan (IC50
 3.162) inhibited
EBOV replication in Vero E6 cells, with up to 1-log differences in
PFU achieved even at the lowest concentration (1g/ml), indicat-
ing that the presence of these compounds inhibited cell entry.
Prior studies demonstrated no cytotoxicity with either of these
polysulfates in Vero cell monolayers (estimated 50% cytotoxic
concentration [CC50],1,000g/ml) (43, 54). Together with the
results of pseudotype virus assays, these findings demonstrate that
GAGs participate in cell entry of EBOV.
DISCUSSION
The attachment to, entry into, and infection of target cells by filo-
viruses are the result of complex virus/cell interactions, including
both nonspecific attachment to cell surfacemolecules and specific
virus/receptor interactions. We conclude from these studies that
filovirus GP attachment occurs at sites on the cell surface that
include HS and possibly other GAG molecules. All filovirus GPs
tested bound specifically to immobilized heparin. This interaction
proved to be dependent on the filovirusGP but did not require the
mucin domain, utilized for the interaction of GP with certain
C-type lectins (5).
The importance of GAGs in filovirus interactions with target
cells was further demonstrated with primary endothelial and liver
cells and in primary macrophages by inhibition in the presence of
heparin and importantly by the significant reduction of EBOV
VLP transduction of primary endothelial cells after heparinase I
treatment. Inhibition onmacrophages was somewhat less impres-
sive, which is not surprising given the numerous other potential
attachment factors present on this particular cell type (5). How-
ever, overall, a role for GP/GAG interactions in filovirus infection
and pathogenesis is likely since the cell types targeted represent
many of the main targets for the virus in vivo. Our results where
filovirus pseudotypes bound specifically to immobilized heparin
and heparin blocked infection in both cell lines and primary cells
suggest that proteoglycans and more specifically HSPGs act as
attachment factors for these viruses. These findings are supported
by the loss of infectivity in primary cells using filamentous VLPs
following heparinase treatment cleaving heparin and/or HS side
chains from HSPGs.
With the description ofNPC1 as a true receptor for EBOV, able
to bind the RBD of GP and apparently mediate membrane fusion
(16–18), an important question remains as to how the filamentous
virus particle reaches the endosomal compartments where NPC1
resides. Whether other specific receptors are required to be en-
gaged to initiate this process or relatively nonspecific, lower-affin-
ity interactions with attachment factors such as HS and other
GAGs are sufficient is open to question. It is unlikely that GAGs
are absolutely necessary for cellular infection, particularly since
their removal with heparinases reduced infectivity only by ap-
proximately 50%. However, it is possible that HSPG is sufficient,
in the absence of other cell surface factors, to shepherd filovirus
particles to intracellular compartments for proteolysis and en-
gagement of NPC1. Interestingly, cross-linking of HSPGs has
been demonstrated to facilitate the trafficking of soluble proteins
into cells viamacropinocytosis (55, 56), themajor route of ingress
for EBOV (13, 14). EBOV uptake is promoted by the receptor
tyrosine kinase Axl in the absence of direct interaction with the
viral GP (57). Recently, drastic effects in virus-cell interactions
caused by proteins involved in bridging virion envelope lipids to
Axl have been described (58). Although the effect of heparinase
treatment strongly points toward the involvement of the surface-
associated GAGs in the entry process, it is a possibility that the
high levels of inhibition achieved by soluble GAGs are the results
of their involvement in similar bridging interactions that facilitate
FIG 7 Soluble polysaccharides inhibit infection of Vero cells by wild-type
EBOV. EBOV was incubated with different concentrations of soluble heparin
or carrageenan and then added to a monolayer of Vero cells for 2 h. Virus was
removed, and the cells were cultured for 8 days in the presence of the com-
pounds. Titers were determined by plaque assay. Results are expressed as
PFU/ml and represent the means SD for duplicate wells.
FIG 6 Antiviral activity of dendrimeric peptide SB105-A10. Huh7 cells were
treated with increasing concentrations of the dendrimer SB105-A10 or the
SB104 negative control 1 h prior to and during the infectionwith concentrated
HIV pseudotypes bearing EBOV, MARV, or Lassa virus envelope glycopro-
teins. Results are expressed as percentages of inhibition and represent the
means SD for duplicate wells. The results are representative of at least three
different experiments.
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attachment of the viruses. Further studies into the relative contri-
bution and role of GAGs in attachment and internalization are
required.
The importance of sulfation levels and patterns for the attach-
ment of other GAG-dependent viruses, such as dengue virus and
RSV, has been described previously (30, 59). Similarly, adequate
levels of sulfation appear to be important for filovirus/GAG inter-
action, since soluble HS, which closely resembles heparin but with
a lower degree of sulfation (60), has no effect on infectivity.
Therein, it could be argued that the interaction of filovirus GPs
with GAGs is somewhat nonspecific and is based mostly on elec-
trostatic effects due to the strong negative charge of the more
sulfated GAGs. However, the significantly higher inhibition levels
observedwith CSA thanwith the closely relatedDS shows that not
only the degree of sulfation but also the structure of the carbohy-
drate backbone is important for the interaction with the filovirus
GPs. The fact that the interaction of filoviruses with the GAGs
shows specific structure/sulfation requirements points out that
the great heterogeneity of GAG expression level, structure, and
sulfation known to occur between different cell typesmight have a
strong effect in the attachment ability of these GPs and thus in
virus tropism. Previous studies showed discrepancies between the
entry mechanism of EBOV when utilizing different pseudotype
systems (retroviral versus rhabdoviral) (13, 14), These studies
suggest that rhabdovirus particles seem tomimic the EBOV virion
more closely (13). With respect to the ability of heparin to inhibit
filovirus GP-mediated infection, we have observed comparable
results in 293T and Huh7 cell lines when the VSV-G-GFP back-
bone was used instead of HIV to produce both EBOV andMARV
pseudotypes (data not shown). Furthermore, we demonstrated
that live EBOV infectivity in cell culture is also inhibited by the
presence of low concentrations of both heparin and carrageenan
polysaccharides. As for the effect of enzymatic removal of heparin
and HS, a similar 50% reduction was observed for HIV pseu-
dotypes and for filamentous EBOV VLPs, which closely resemble
infectious Ebola virus particles, by electron microscopy (61, 62).
The reliance on GAGs for at least efficient initial attachment
suggests that targeting these interactions could be an effective an-
tiviral strategy. Indeed, in addition to soluble forms of the GAGs
themselves, we demonstrated inhibition of GAG-dependent vi-
ruses by carrageenan. Inhibition most likely takes place by chem-
ically mimicking HS, thereby competing against initial virion at-
tachment to the cell surface GAGs. Since carrageenan is widely
used in the food industry, it is being tested for use as a broad-
spectrum microbicide (46). Novel peptidic antiviral drugs, and
more specifically the peptide dendrimer SB105-A10, have
emerged as potent inhibitors of many viruses that act via binding
to HSPGs on the cell surface (49–51). As we expected, SB105-A10
was able to efficiently inhibit filoviral infections, and as in the
previous studies, its antiviral activity was dependent on the spe-
cific amino acid sequences of the peptide surface groups attached
to the dendrimer scaffold, since surface group sequence variants,
such as SB104, reduced or completely abolished the antiviral ac-
tion.
We conclude that filoviruses utilize HSPGs and possibly other
cell surface GAGs for the initial attachment to their target cells.
This step is not common to another hemorrhagic virus, Lassa
virus, which interacts with cells in a GAG-independent manner.
These findings not only contribute to furthering our understand-
ing of the filovirus entry process but also reveal a new step in the
virus cycle that can be the target for antiviral strategies that have
already been proven effective for the inhibition of other viruses.
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